Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Serlopitant
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Menlo Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger
Details : The combined company already has an approved, commercial-stage product, AMZEEQ™, and several late-stage product candidates.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 03, 2020
Lead Product(s) : Serlopitant
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Menlo Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Foamix Announces Publication of Phase 3 Studies Evaluating FMX103
Details : Both studies demonstrated statistically significant superiority of FMX103 compared with vehicle in both primary endpoints of absolute inflammatory lesion reduction.
Product Name : Amzeeq
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 02, 2020
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Cutia Therapeutics
Deal Size : $11.0 million
Deal Type : Licensing Agreement
Details : Cutia will have an exclusive license to obtain regulatory approval and sell AMZEEQ. Foamix is to supply Cutia with the finished licensed products for clinical and commercial use.
Product Name : Amzeeq
Product Type : Other Small Molecule
Upfront Cash : $10.0 million
April 23, 2020
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Cutia Therapeutics
Deal Size : $11.0 million
Deal Type : Licensing Agreement